Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026
Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026
Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026
Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026
Company Drug

Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines

Fineline Cube Jun 28, 2022

China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...

Company Drug

Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment

Fineline Cube Jun 28, 2022

US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...

Company

Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal

Fineline Cube Jun 28, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...

Company Deals

ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline

Fineline Cube Jun 28, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study

Fineline Cube Jun 28, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...

Company Drug

Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials

Fineline Cube Jun 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...

Drug

Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator

Fineline Cube Jun 28, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...

Company Medical Device

Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5

Fineline Cube Jun 28, 2022

China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest...

Company Deals

Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma

Fineline Cube Jun 28, 2022

China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....

Policy / Regulatory

7th National VBP Round Venue Moved to Nanjing from Shanghai

Fineline Cube Jun 27, 2022

In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not...

Company Drug

Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment

Fineline Cube Jun 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022

Fineline Cube Jun 27, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...

Company Drug

Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial

Fineline Cube Jun 27, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...

Company Deals

Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services

Fineline Cube Jun 27, 2022

China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm...

Medical Device

NMPA Approves Senscure’s Cryoablation Catheter and Kangduo’s Laparoscopic Surgery System

Fineline Cube Jun 27, 2022

The National Medical Products Administration (NMPA) has approved two innovative medical devices in China: Ningbo...

Company Deals

Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline

Fineline Cube Jun 27, 2022

Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...

Company Deals

PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform

Fineline Cube Jun 27, 2022

Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions”...

Company Drug

GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis

Fineline Cube Jun 27, 2022

UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...

Company Deals

Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies

Fineline Cube Jun 27, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot...

Drug

Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review

Fineline Cube Jun 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...

Posts pagination

1 … 611 612 613 … 619

Recent updates

  • Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
  • Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
  • Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
  • Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
  • Marubeni Launches Xenleta in China After Complex Licensing Journey
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.